Novavax Inc (NVAX) Stock Price & Analysis
Novavax Inc (NVAX) fell 4.66% to USD 7.46 as of July 25, 2026 at 01:45 UTC, according to Nexqual real-time market data.
NVAX last closed at USD 7.83; the session ranged USD 7.45–7.93 on volume of 3,144,750 shares. Market capitalization is $1.23B, with a 52-week range of USD 6.2–11.97 (NMS). Source: Nexqual, July 25, 2026 at 01:45 UTC.
Key Statistics (as of July 25, 2026 at 01:45 UTC)
| Price | USD 7.46 |
|---|---|
| Change | ▼ 4.66% (down) |
| Previous Close | USD 7.83 |
| Open | USD 7.9 |
| Day Range | USD 7.45 – 7.93 |
| 52-Week Range | USD 6.2 – 11.97 |
| Volume | 3,144,750 shares |
| Market Cap | $1.23B |
| Exchange | NMS |
Technical Analysis (NVAX)
Nexqual's technical model rates NVAX "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:45 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.66 (oversold) |
| vs SMA50 | Below (USD 9.16) |
| MACD | -0.4 (negative) |
Analyst Ratings (NVAX)
Wall Street analysts rate NVAX "Buy" based on 9 analysts, with a mean price target of USD 14.11 (range USD 7–25), per Nexqual as of July 25, 2026 at 01:45 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 14.11 |
| High Target | USD 25 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 5 / 1 / 3 |
Earnings (NVAX)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.42 |
| Revenue Estimate | $52.06M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.06 vs est -0.24 ▲ beat |
| 2025-12-31 | USD 0.11 vs est -0.49 ▲ beat |
| 2025-09-30 | USD -1.25 vs est -1.17 ▼ miss |
| 2025-06-30 | USD 0.62 vs est -0.08 ▲ beat |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financials & Fundamentals (NVAX)
| Total Revenue | $596.34M |
|---|---|
| Revenue Growth (YoY) | -79.10% |
| Gross Margin | +27.49% |
| Operating Margin | -7.19% |
| Profit Margin | -14.73% |
| Current Ratio | 2.48 |
| Total Cash | $790.33M |
| Total Debt | $295.06M |
| Free Cash Flow | $58.57M |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Financial Health Score (NVAX)
Nexqual rates Novavax Inc's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 01:45 UTC.
| Growth | Strong — Revenue +65% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 27%, operating -7% |
| Balance Sheet | Mixed — $790M cash vs $295M debt, net cash position |
| Cash Flow | Solid — FCF $59M, 5% margin |
| Efficiency | Mixed — No data |
Ownership (NVAX)
| Insider Ownership | +5.08% |
|---|---|
| Institutional Ownership | +69.48% |
| Shares Outstanding | 164.44M |
| Float | 141.47M |
| Short % of Float | +28.04% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
Leadership (NVAX)
Novavax Inc is led by John Charles Jacobs (age 58), President, CEO & Director, per Nexqual as of July 25, 2026 at 01:45 UTC.
| President, CEO & Director | John Charles Jacobs (age 58) |
|---|---|
| Executive VP, CFO & Treasurer | James Patrick Kelly C.F.A. (age 59) |
| Executive VP & Chief Strategy Officer | Elaine O'Hara (age 57) |
| Executive VP & COO | Richard P. Crowley (age 68) |
| Vice President of Investor Relations | Luis Sanay C.F.A. |
Major Backers & Investors (NVAX)
Notable institutional backers of Novavax Inc include Shah Capital Management, Shaw D.E. & Co., Inc., Sanofi, according to Nexqual as of July 25, 2026 at 01:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Shah Capital Management | 9.03% |
| Shaw D.E. & Co., Inc. | 4.69% |
| Sanofi | 4.18% |
| Bank of America Corporation | 4.04% |
| UBS Group AG | 2.72% |
| Fidelity | 0.9% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 16.47% |
| BlackRock | 11.32% |
| State Street | 10.02% |
| Geode Capital | 2.37% |
Source: Nexqual, July 25, 2026 at 01:45 UTC.
From Novavax Inc's Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
- The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
- It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRNA | Moderna, Inc. | USD 54.07 | ▼ 6.89% |
| INO | Inovio Pharmaceuticals, Inc. | USD 0.97 | ▼ 8.49% |
| BNTX | BioNTech SE | USD 89.33 | ▼ 2.72% |
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 3.13% |
| AZN | AstraZeneca PLC | USD 169.26 | ▼ 0.28% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:45 UTC. This page is informational and not investment advice.